Andrew E. Skodol, II, M.D.
Name, Degree: Andrew E. Skodol, M.D.
Role(s) in Task Force and Work Group: Chair, Personality and Personality Disorders Work Group
Institutional Affiliation(s): President, Institute for Mental Health Research
City, State: Phoenix, AZ
Biographical Sketch:
Andrew E. Skodol, M.D.
Chair, Personality Disorders Work Group
Member, DSM-V Task Force
President, Institute for Mental Health Research
Research Professor of Psychiatry, University of Arizona College of Medicine
Phoenix, AZ
Dr. Skodol is a graduate of Yale University and the University of Pennsylvania School of Medicine. He received his psychiatric training at the Albert Einstein College of Medicine. Dr. Skodol was a Research Psychiatrist at the New York State Psychiatric Institute until 2007, Director of the Department of Personality Studies from 1997 to 2007, and Deputy Director of the Institute from 2000 through 2003. In January 2007, he became President of the Institute for Mental Health Research in Arizona.
Dr. Skodol Chairs the Steering Committee and is a Principal Investigator of the NIMH-funded Collaborative Longitudinal Personality Disorders Study (CLPS). He has published extensively on the topics of clinical psychiatric diagnosis, the assessment of stress and psychosocial functioning, and personality disorders.
Dr. Skodol led national training efforts for DSM-III. He served on DSM-III-R subcommittees on psychotic disorders, personality disorders, and the multiaxial system and conducted a review of empirical literature. In addition, Dr. Skodol authored the book Problems in Differential Diagnosis: From DSM-III to DSM-III-R in Clinical Practice and co-edited the DSM-III, DSM-III-R, DSM-IV, and DSM-IV-TR Casebooks and the American Psychiatric Publishing Textbook of Personality Disorders.
Dr. Skodol is a Distinguished Fellow of the American Psychiatric Association; Fellow of the American Psychopathological Association; Member of the American College of Psychiatrists; Member of the Section on Classification, Diagnostic Assessment, and Nomenclature of the World Psychiatric Association; and Chair of the Collaborative Research Committee of the International Society for the Study of Personality Disorders.
Uncompensated affiliations with non-profit or advocacy organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V : Three calendar years before nomination and Each year thereafter through the present calendar year. (For 2008, activities to date and commitments for remainder of year.)
|
Non-Profit and Advocacy Organizations |
Year(s) |
Role |
|
National Education Alliance for Borderline Personality Disorder |
2003-2008 |
Scientific Advisory Board |
The two tables below represent Dr. Skodol’s disclosure of significant interests and affiliations for: (1) The time period including the 3 years prior to nomination to serve on the DSM-V Task Force; the calendar year in which nomination to the Task Force occurred; through the calendar year in which the nomination was approved; and (2) the time period including the calendar year after approval, and each successive year to the present.
Dr. Skodol has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed $10,000 in any calendar year.
|
KEY NUMBER:
1. Consultation Fees (include scientific advisory boards)
2. Full- or Part-time Employee
3. Industry-related Grant-Research Support received or pending
4. Honoraria (includes Speakers’ Bureau)
5. Stock or other financial options |
6. Expert testimony
7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)
8. Patents received or pending
9. Officer, director/trustee, executive (specify)
10. Other (specify) |
Disclosure of significant interests including: Three (3) calendar years before nomination, the calendar year of nomination, through the calendar year of approval to serve on the DSM-V Task Force
|
Commercial or Other Organization |
Year(s) |
Key #(s) |
|
Borderline Personality Disorder Research Foundation |
2003-2006 |
1 |
|
Carlet Garrison |
2003 |
6 |
|
Podvey Sachs |
2004-2005 |
6 |
|
Peabody Arnold |
2004 |
6 |
|
Fireman’s Fund |
2004-2005 |
6 |
|
Johnson & Johnson |
2003-2006 |
5 |
|
Pfizer |
2003-2006 |
5 |
|
Eli Lilly |
2003-2006 |
5 |
Disclosure of significant interests Beginning with the calendar year after APA Board of Trustees approval to serve on the DSM-V Task Force, to the present. (For 2008, activities to date and commitments for remainder of year.)
|
Commercial or Other Organization |
Year(s) |
Key #(s) |
|
Johnson & Johnson |
2007 |
5 |
|
Pfizer |
2007 |
5 |
|
Eli Lilly |
2007 |
5 |